Comparison of halving the irradiation time or the verteporfin dose in photodynamic therapy for chronic central serous chorioretinopathy

Yusuke Shiode, Yuki Morizane, Shuhei Kimura, Mio Hosokawa, Tetsuhiro Kawata, Shinichiro Doi, Mika Hosogi, Atsushi Fujiwara, Fumio Shiraga

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: To compare the efficacy and safety of photodynamic therapy using reduced irradiation time or reduced verteporfin dose for chronic central serous chorioretinopathy. Methods: Between April 2011 and December 2013, 45 eyes with chronic central serous chorioretinopathy (43 consecutive patients) were treated with photodynamic therapy, using either half the irradiation time (18 eyes) or half the verteporfin dose (27 eyes). Outcome measures at follow-up, over at least 3 months, were complete resolution of serous retinal detachment, best-corrected visual acuity, and central retinal thickness. Results: After 3 months, serous retinal detachment had completely resolved in 88.8% of eyes in both treatment groups, which were therefore not significantly different. The logarithm of the minimal angle of resolution best-corrected visual acuity (Snellen equivalent) improved from 0.245 (20/35) to 0.130 (20/27) (P , 0.05, paired t-test) in the reduced time group and from 0.283 (20/38) to 0.138 (20/27) (P , 0.05) in the reduced verteporfin group. Final best-corrected visual acuities in the 2 groups were not significantly different. Central retinal thicknesses dropped from 337.0 mm to 146.6 mm (P , 0.05) in the reduced time group and from 343.5 mm to 166.9 mm (P , 0.05) in the reduced verteporfin group. No ocular or systemic side effects were observed. Conclusion: Reduced irradiation time and reduced verteporfin dose were equally effective and safe in photodynamic therapy for chronic central serous chorioretinopathy.

Original languageEnglish
Pages (from-to)2498-2504
Number of pages7
JournalRetina
Volume35
Issue number12
DOIs
Publication statusPublished - 2015

Fingerprint

Central Serous Chorioretinopathy
Photochemotherapy
Visual Acuity
Retinal Detachment
Outcome Assessment (Health Care)
verteporfin
Safety

Keywords

  • Central serous chorioretinopathy
  • Photodynamic therapy
  • Verteporfin

ASJC Scopus subject areas

  • Ophthalmology

Cite this

@article{e93d000d7a9b486e89ff2329d11a087e,
title = "Comparison of halving the irradiation time or the verteporfin dose in photodynamic therapy for chronic central serous chorioretinopathy",
abstract = "Purpose: To compare the efficacy and safety of photodynamic therapy using reduced irradiation time or reduced verteporfin dose for chronic central serous chorioretinopathy. Methods: Between April 2011 and December 2013, 45 eyes with chronic central serous chorioretinopathy (43 consecutive patients) were treated with photodynamic therapy, using either half the irradiation time (18 eyes) or half the verteporfin dose (27 eyes). Outcome measures at follow-up, over at least 3 months, were complete resolution of serous retinal detachment, best-corrected visual acuity, and central retinal thickness. Results: After 3 months, serous retinal detachment had completely resolved in 88.8{\%} of eyes in both treatment groups, which were therefore not significantly different. The logarithm of the minimal angle of resolution best-corrected visual acuity (Snellen equivalent) improved from 0.245 (20/35) to 0.130 (20/27) (P , 0.05, paired t-test) in the reduced time group and from 0.283 (20/38) to 0.138 (20/27) (P , 0.05) in the reduced verteporfin group. Final best-corrected visual acuities in the 2 groups were not significantly different. Central retinal thicknesses dropped from 337.0 mm to 146.6 mm (P , 0.05) in the reduced time group and from 343.5 mm to 166.9 mm (P , 0.05) in the reduced verteporfin group. No ocular or systemic side effects were observed. Conclusion: Reduced irradiation time and reduced verteporfin dose were equally effective and safe in photodynamic therapy for chronic central serous chorioretinopathy.",
keywords = "Central serous chorioretinopathy, Photodynamic therapy, Verteporfin",
author = "Yusuke Shiode and Yuki Morizane and Shuhei Kimura and Mio Hosokawa and Tetsuhiro Kawata and Shinichiro Doi and Mika Hosogi and Atsushi Fujiwara and Fumio Shiraga",
year = "2015",
doi = "10.1097/IAE.0000000000000621",
language = "English",
volume = "35",
pages = "2498--2504",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Comparison of halving the irradiation time or the verteporfin dose in photodynamic therapy for chronic central serous chorioretinopathy

AU - Shiode, Yusuke

AU - Morizane, Yuki

AU - Kimura, Shuhei

AU - Hosokawa, Mio

AU - Kawata, Tetsuhiro

AU - Doi, Shinichiro

AU - Hosogi, Mika

AU - Fujiwara, Atsushi

AU - Shiraga, Fumio

PY - 2015

Y1 - 2015

N2 - Purpose: To compare the efficacy and safety of photodynamic therapy using reduced irradiation time or reduced verteporfin dose for chronic central serous chorioretinopathy. Methods: Between April 2011 and December 2013, 45 eyes with chronic central serous chorioretinopathy (43 consecutive patients) were treated with photodynamic therapy, using either half the irradiation time (18 eyes) or half the verteporfin dose (27 eyes). Outcome measures at follow-up, over at least 3 months, were complete resolution of serous retinal detachment, best-corrected visual acuity, and central retinal thickness. Results: After 3 months, serous retinal detachment had completely resolved in 88.8% of eyes in both treatment groups, which were therefore not significantly different. The logarithm of the minimal angle of resolution best-corrected visual acuity (Snellen equivalent) improved from 0.245 (20/35) to 0.130 (20/27) (P , 0.05, paired t-test) in the reduced time group and from 0.283 (20/38) to 0.138 (20/27) (P , 0.05) in the reduced verteporfin group. Final best-corrected visual acuities in the 2 groups were not significantly different. Central retinal thicknesses dropped from 337.0 mm to 146.6 mm (P , 0.05) in the reduced time group and from 343.5 mm to 166.9 mm (P , 0.05) in the reduced verteporfin group. No ocular or systemic side effects were observed. Conclusion: Reduced irradiation time and reduced verteporfin dose were equally effective and safe in photodynamic therapy for chronic central serous chorioretinopathy.

AB - Purpose: To compare the efficacy and safety of photodynamic therapy using reduced irradiation time or reduced verteporfin dose for chronic central serous chorioretinopathy. Methods: Between April 2011 and December 2013, 45 eyes with chronic central serous chorioretinopathy (43 consecutive patients) were treated with photodynamic therapy, using either half the irradiation time (18 eyes) or half the verteporfin dose (27 eyes). Outcome measures at follow-up, over at least 3 months, were complete resolution of serous retinal detachment, best-corrected visual acuity, and central retinal thickness. Results: After 3 months, serous retinal detachment had completely resolved in 88.8% of eyes in both treatment groups, which were therefore not significantly different. The logarithm of the minimal angle of resolution best-corrected visual acuity (Snellen equivalent) improved from 0.245 (20/35) to 0.130 (20/27) (P , 0.05, paired t-test) in the reduced time group and from 0.283 (20/38) to 0.138 (20/27) (P , 0.05) in the reduced verteporfin group. Final best-corrected visual acuities in the 2 groups were not significantly different. Central retinal thicknesses dropped from 337.0 mm to 146.6 mm (P , 0.05) in the reduced time group and from 343.5 mm to 166.9 mm (P , 0.05) in the reduced verteporfin group. No ocular or systemic side effects were observed. Conclusion: Reduced irradiation time and reduced verteporfin dose were equally effective and safe in photodynamic therapy for chronic central serous chorioretinopathy.

KW - Central serous chorioretinopathy

KW - Photodynamic therapy

KW - Verteporfin

UR - http://www.scopus.com/inward/record.url?scp=84948468144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948468144&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000621

DO - 10.1097/IAE.0000000000000621

M3 - Article

C2 - 26035398

AN - SCOPUS:84948468144

VL - 35

SP - 2498

EP - 2504

JO - Retina

JF - Retina

SN - 0275-004X

IS - 12

ER -